BioHarvest Sciences Inc. (BHST) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 8, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 40-F for FY2025, filed Mar 31, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BHST SEC filings page.
BioHarvest Sciences Inc. (BHST) reported $34.5M in revenue for fiscal year 2025, up 37.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is scaling and margins are improving, but the business still converts growth into recurring cash needs funded externally.
From FY2023 to FY2025, gross margin widened from44.5% to59.3% , indicating improving product-level economics. Operating margin improved from-78.7% to-16.2% but stayed negative, so better gross economics have not yet covered the operating cost base.
FY2025's net loss of
The current ratio climbed from 0.3 to 4.0 between FY2023 and FY2025, shifting short-term coverage from tight to much higher on the reported balance sheet. Yet FY2025 financing cash flow of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of BioHarvest Sciences Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
BioHarvest Sciences Inc. held $23.0M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $7.2M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and BioHarvest Sciences Inc. scores 62/100 among other emerging companies.
BioHarvest Sciences Inc. had 23M shares outstanding at the end of fiscal year 2025, against 17M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and BioHarvest Sciences Inc. scores 26/100 among other emerging companies.
Not available for BioHarvest Sciences Inc., and counted as zero in the overall score.
BioHarvest Sciences Inc. reported revenue of $34.5M in fiscal year 2025, against $25.2M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and BioHarvest Sciences Inc. scores 82/100 among other emerging companies.
BioHarvest Sciences Inc.'s operations used $7.2M of cash in fiscal year 2025, against $6.7M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and BioHarvest Sciences Inc. scores 54/100 among other emerging companies.
Not available for BioHarvest Sciences Inc., and counted as zero in the overall score.
BioHarvest Sciences Inc. passes 3 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 2 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
BioHarvest Sciences Inc. reported a net loss of $11.1M while operations used $7.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
BioHarvest Sciences Inc. held $23.0M in cash as of Q4 2025; long-term debt is not reported for that period.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
BHST Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
BHST Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2540-F | Q4'2440-F | Q4'2310-K |
|---|---|---|---|
| Current Assets | $30.5M+288.2% | $7.9M-13.2% | $9.1M |
| Cash & Equivalents | $23.0M+863.4% | $2.4M-55.4% | $5.4M |
| Short-Term Investments | $0 | $0 | $0 |
| Inventory | $4.6M+24.7% | $3.7M+48.2% | $2.5M |
| Accounts Receivable | $2.0M+77.5% | $1.1M+38.1% | $808K |
| Long-Term Investments | $0 | $0 | $0 |
| Current Liabilities | $7.7M-46.1% | $14.3M-46.1% | $26.5M |
| Non-Current Liabilities | $14.5M+54.4% | $9.4M+177.8% | $3.4M |
| Total Equity | $25.4M+1813.4% | $1.3M+109.0% | -$14.9M |
| Retained Earnings | -$107.6M-11.5% | -$96.4M-15.5% | -$83.5M |
Not reported in any period shown, so not listed: Total Assets, Goodwill, Total Liabilities, Long-Term Debt.
BHST Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
BHST Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Debt-to-Equity, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| BioHarvest Sciences Inc. BHST | FY2025 | $34.5M | -$11.1M | -32.3% | $33.8M | 37/100 |
| Lifevantage Corporation LFVN | FY2026 | $182.6M | $5.1M | 2.8% | $75.5M | 49/100 |
| FitLife Brands, Inc. FTLF | FY2025 | $15.9M | $6.3M | 39.7% | $86.7M | 55/100 |
| Hain Celestial Group Inc HAIN | FY2026 | $1.4B | -$304.9M | -22.5% | $48.2M | 22/100 |
| DDC Enterprise Limited DDC | FY2025 | $39.2M | -$48.3M | N/A | $11.3M | 20/100 |
Where BioHarvest Sciences Inc. Ranks
Frequently Asked Questions
What is BioHarvest Sciences Inc.'s annual revenue?
BioHarvest Sciences Inc. (BHST) reported $34.5M in total revenue for fiscal year 2025. This represents a 37.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is BioHarvest Sciences Inc.'s revenue growing?
BioHarvest Sciences Inc. (BHST) revenue grew by 37.0% year-over-year, from $25.2M to $34.5M in fiscal year 2025.
Is BioHarvest Sciences Inc. profitable?
No, BioHarvest Sciences Inc. (BHST) reported a net income of -$11.1M in fiscal year 2025, with a net profit margin of -32.3%.
What is BioHarvest Sciences Inc.'s EBITDA?
BioHarvest Sciences Inc. (BHST) had EBITDA of -$4.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is BioHarvest Sciences Inc.'s gross margin?
BioHarvest Sciences Inc. (BHST) had a gross margin of 59.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is BioHarvest Sciences Inc.'s operating margin?
BioHarvest Sciences Inc. (BHST) had an operating margin of -16.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is BioHarvest Sciences Inc.'s net profit margin?
BioHarvest Sciences Inc. (BHST) had a net profit margin of -32.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is BioHarvest Sciences Inc.'s return on equity (ROE)?
BioHarvest Sciences Inc. (BHST) has a return on equity of -43.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is BioHarvest Sciences Inc.'s free cash flow?
BioHarvest Sciences Inc. (BHST) recorded an outflow of $9.6M in free cash flow during fiscal year 2025. This represents a -0.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is BioHarvest Sciences Inc.'s operating cash flow?
BioHarvest Sciences Inc. (BHST) recorded an outflow of $7.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are BioHarvest Sciences Inc.'s capital expenditures?
BioHarvest Sciences Inc. (BHST) invested $2.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is BioHarvest Sciences Inc.'s current ratio?
BioHarvest Sciences Inc. (BHST) had a current ratio of 3.97 as of fiscal year 2025, which is generally considered healthy.
What is BioHarvest Sciences Inc.'s P/E ratio?
BioHarvest Sciences Inc. (BHST) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $33.8M as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is BioHarvest Sciences Inc.'s price-to-sales ratio?
BioHarvest Sciences Inc. (BHST) trades at 1.0x sales, its market capitalization divided by revenue of $34.5M revenue, FY2025. The market capitalization is $33.8M as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does BioHarvest Sciences Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, BioHarvest Sciences Inc. (BHST) held $23.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $7.2M over that year. Dividing the one by the other, the reported balance equals about 38 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is BioHarvest Sciences Inc.'s Piotroski F-Score?
BioHarvest Sciences Inc. (BHST) has a Piotroski F-Score of 3 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are BioHarvest Sciences Inc.'s earnings high quality?
BioHarvest Sciences Inc. (BHST) reported a net loss of $11.1M while operations used $7.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is BioHarvest Sciences Inc.?
BioHarvest Sciences Inc. (BHST) scores 37 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.